Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a condition that raises an important question for many affected men: can gynaecomastia be reversed? The answer depends on several factors, including how long the condition has been present, its underlying cause, and the treatment approach taken. In some cases, particularly in adolescents or when triggered by a medication, spontaneous or medically assisted resolution is possible. In longstanding cases, surgery may be the only effective option. This article explores the full range of reversal possibilities, from hormonal and medical treatments to surgical intervention, and explains when to seek medical advice.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an oestrogen-androgen imbalance, with common triggers including puberty, medications such as spironolactone and finasteride, and conditions such as hypogonadism or liver cirrhosis.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery mass beneath the nipple area. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth and is typically associated with obesity. Gynaecomastia can affect one or both breasts and may cause tenderness or discomfort, though it is not usually a sign of serious illness.

The condition arises from an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Even in healthy males, small amounts of oestrogen are produced, but when this ratio shifts — either through increased oestrogen or reduced testosterone — glandular tissue can proliferate. Common underlying causes include:

• Physiological changes: Gynaecomastia is common in newborns (due to maternal oestrogen), adolescents (during puberty), and older men (due to declining testosterone).

• Medications: A range of drugs can trigger gynaecomastia. Commonly implicated agents include spironolactone, cimetidine, digoxin, ketoconazole, some antipsychotics, certain antiretrovirals, 5-alpha-reductase inhibitors (finasteride and dutasteride), anti-androgens such as bicalutamide, and GnRH analogues. Anabolic steroids and exogenous androgens are also recognised causes. The British National Formulary (BNF) and individual Summary of Product Characteristics (SmPC) documents list gynaecomastia as an adverse effect for relevant medicines; the MHRA issues Drug Safety Updates when new signals emerge and operates the Yellow Card scheme for reporting suspected adverse drug reactions.

• Medical conditions: Hypogonadism (including Klinefelter syndrome), hyperthyroidism, liver cirrhosis, chronic kidney disease, and testicular tumours can all disrupt hormonal balance.

• Recreational substances: Cannabis, alcohol, and anabolic steroids are recognised contributing factors.

Understanding the root cause is essential, as it directly determines whether gynaecomastia can be reversed and which treatment pathway is most appropriate. In many adolescent cases, the condition resolves spontaneously within one to two years without any intervention, as noted in NICE Clinical Knowledge Summaries (CKS) and on the NHS website.

Medical and Hormonal Treatments

Medical treatment is most effective in the early phase; no UK-licensed medicines exist for gynaecomastia, but off-label SERMs such as tamoxifen may reduce tissue volume under specialist supervision.

The first step in managing gynaecomastia medically is identifying and addressing any reversible underlying cause. If a medication is responsible, a GP may review the prescription and consider switching to an alternative where clinically appropriate — early discontinuation of the causative medicine improves the likelihood of regression. Similarly, treating an underlying condition such as hyperthyroidism or hypogonadism can lead to gradual regression of breast tissue, particularly if the gynaecomastia is in its early, proliferative phase (typically within the first 12 months of onset).

It is important to note that no medicines are currently licensed in the UK specifically for the treatment of gynaecomastia. Any pharmacological treatment is therefore off-label, and prescribing is usually specialist-initiated following shared decision-making. Access varies by local Integrated Care Board (ICB) formulary and specialist input; there is no single national NHS commissioning policy. The most commonly discussed agents include:

• Tamoxifen: A selective oestrogen receptor modulator (SERM) that blocks oestrogen's action on breast tissue. Some evidence supports its use in reducing pain and tissue volume, particularly in pubertal or drug-induced gynaecomastia. It is used off-label in this context. As with all SERMs, there is a small increased risk of venous thromboembolism (VTE); this should be discussed with patients as part of shared decision-making. Refer to the BNF and tamoxifen SmPC for full prescribing information.

• Raloxifene: Another SERM occasionally used off-label, with some studies suggesting comparable or superior efficacy to tamoxifen in reducing glandular tissue. Similar safety considerations apply. Evidence remains limited and use should be under specialist guidance.

• Aromatase inhibitors (e.g., anastrozole): These reduce the conversion of androgens to oestrogen. Evidence for their use in gynaecomastia is limited, and most UK guidance does not routinely recommend them outside specific endocrine contexts under specialist supervision, given their adverse-effect profile and uncertain benefit.

Medical treatments are most effective during the active, early phase of gynaecomastia. Once fibrous tissue has replaced glandular tissue — typically after 12 months — pharmacological reversal becomes significantly less likely. NICE CKS recommends a watchful waiting approach for mild or physiological cases before escalating to medical or surgical intervention. If you are taking any medicine for gynaecomastia and experience unexpected side effects, you can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Surgical Options for Gynaecomastia in the UK

Surgery — subcutaneous mastectomy and/or liposuction — is the definitive treatment for longstanding gynaecomastia, though NHS funding requires meeting strict criteria set by local ICB policy.

When gynaecomastia is longstanding, causes significant psychological distress, or has not responded to conservative or medical management, surgery may be considered. NHS funding for surgical treatment is subject to strict criteria and varies by local ICB policy; NHS England's Evidence-Based Interventions (EBI) programme sets out restrictions on procedures where clinical benefit is limited or where specific thresholds must be met. Criteria typically include documented psychological impact, a stable underlying cause, and failure of non-surgical approaches. Patients who do not meet NHS criteria may seek treatment through private healthcare providers.

The two main surgical techniques used are:

• Liposuction: Suitable when excess fatty tissue is the predominant component. A small cannula is inserted through a minor incision to remove fat. This approach has a shorter recovery time but may not adequately address true glandular tissue.

• Mastectomy (subcutaneous or glandular excision): Involves the surgical removal of glandular breast tissue, usually through a periareolar incision. This is the definitive treatment for true gynaecomastia and is often combined with liposuction for optimal cosmetic results. Excised tissue is routinely sent for histopathological examination.

In more severe cases — classified using the Simon or Rohrich grading systems — skin excision may also be required to address excess skin and achieve a flat chest contour. Surgical outcomes are generally considered permanent, provided the underlying hormonal cause has been addressed. However, if the causative factor (such as ongoing anabolic steroid use or an untreated hormonal condition) persists, recurrence is possible.

Complications, though uncommon, can include scarring, asymmetry, changes in nipple sensation, haematoma, and infection. Patients considering surgery should ensure their provider is registered with the Care Quality Commission (CQC) and that their surgeon is on the GMC Specialist Register in an appropriate specialty (such as plastic surgery). Membership of the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) or the British Association of Aesthetic Plastic Surgeons (BAAPS) is optional but provides additional reassurance of specialist training and standards.

Factors That Affect Whether Gynaecomastia Can Be Reversed

Reversibility depends primarily on duration, with early-phase gynaecomastia more likely to respond to treatment; longstanding cases with fibrosis are unlikely to resolve without surgery.

Whether gynaecomastia can be reversed depends on several interconnected factors, and outcomes vary considerably between individuals. Understanding these variables helps set realistic expectations and guides clinical decision-making.

Duration of the condition is one of the most significant determinants. In the early, active phase — generally within the first six to twelve months — breast tissue is predominantly glandular and more responsive to hormonal changes or medical treatment. Over time, this tissue undergoes fibrosis and becomes denser and less responsive. Longstanding gynaecomastia (beyond 12 months) is unlikely to resolve without surgical intervention, as outlined in NICE CKS guidance.

Underlying cause also plays a critical role:

• Physiological gynaecomastia in adolescents frequently resolves spontaneously.

• Drug-induced gynaecomastia may regress after the offending medication is discontinued early, though this is not guaranteed.

• Gynaecomastia secondary to a treatable medical condition (e.g., hypogonadism or hyperthyroidism) may improve with appropriate treatment of the underlying disorder.

• Klinefelter syndrome is associated with persistent gynaecomastia and a higher risk of male breast cancer; specialist endocrine input is advisable.

• Gynaecomastia linked to ongoing anabolic steroid use or untreated systemic disease is less likely to reverse without addressing the root cause.

Severity and grade of the gynaecomastia also influence reversibility. Mild cases with minimal glandular involvement have a better prognosis for non-surgical resolution than moderate or severe cases with significant tissue hypertrophy or skin excess.

Age and overall health are additional considerations. Younger individuals with active hormonal fluctuations may experience natural resolution, whereas older men with age-related testosterone decline may require more active management. Body weight is also relevant — weight loss in overweight individuals can reduce pseudogynaecomastia and may modestly improve true gynaecomastia by lowering peripheral oestrogen production from adipose tissue.

When to See a GP About Breast Tissue Changes

Men should see a GP promptly for any new breast lump, nipple discharge, or rapid tissue growth; NICE NG12 recommends urgent two-week-wait referral for suspicious features in men aged 50 or over.

Many men feel embarrassed about breast changes and delay seeking medical advice, but early assessment is important both for effective management and to rule out rare but serious underlying conditions. You should arrange an appointment with your GP if you notice:

• A new lump or swelling beneath one or both nipples

• Breast pain or tenderness that is persistent or worsening

• Nipple discharge, particularly if it is bloodstained

• Nipple retraction (the nipple turning inward)

• Rapid or asymmetric growth of breast tissue

• Skin changes over the breast, such as dimpling, puckering, or ulceration

• Swollen lymph nodes in the armpit

Whilst gynaecomastia itself is benign, male breast cancer — though rare, accounting for less than 1% of all breast cancers in the UK — can present similarly. NICE guideline NG12 (Suspected Cancer: Recognition and Referral) recommends that men aged 50 or over with a unilateral, firm subareolar mass with or without nipple discharge or distortion should be referred urgently via the two-week-wait (2WW) pathway to a breast clinic. Any unexplained breast lump in a male should be assessed promptly regardless of age.

Your GP will typically take a full medical and medication history and examine the breast tissue. Baseline investigations recommended by NICE CKS include morning serum testosterone, LH, FSH, oestradiol, prolactin, TSH, liver function tests (LFTs), and renal function (U&E). Serum hCG (and AFP where indicated) should be considered if a testicular or other germ cell tumour is suspected. Testicular ultrasound or breast imaging may also be arranged depending on clinical findings.

Referral to an endocrinologist, urologist, or breast surgeon may follow depending on findings. If a drug cause is identified, your GP can liaise with the relevant prescribing team. For adolescents, reassurance and a watchful waiting approach are often appropriate, with follow-up arranged to monitor for spontaneous resolution.

If you are experiencing psychological distress related to gynaecomastia — including anxiety, low self-esteem, or avoidance of social situations — do mention this to your GP. Psychological impact is a recognised factor in NHS referral decisions for surgical treatment, and support through talking therapies may also be beneficial alongside any physical management.

Frequently Asked Questions